Halozyme Therapeutics | HALO - Market Capitalization


Halozyme Therapeutics reported $8.94B in Market Capitalization this February of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 4.16B 364M Feb/2026
Agios Pharmaceuticals USD 1.6B 16M Feb/2026
Alnylam Pharmaceuticals USD 39.74B 12.8B Feb/2026
Amarin USD 341M 4M Sep/2025
Amgen USD 201.45B 25.2B Feb/2026
Baxter International USD 9.54B 279M Feb/2026
Cara Therapeutics USD 46M 23M Jun/2025
Cytokinetics USD 8.27B 504M Feb/2026
DBV Technologies USD 274M 17M Sep/2025
Eli Lilly USD 1.01T 3.37B Feb/2026
Esperion Therapeutics USD 340M 235M Dec/2023
Halozyme Therapeutics USD 10.23B 2.31B Feb/2026
Intrexon USD 363M 69M Sep/2023
Ionis Pharmaceuticals USD 11.8B 1.01B Feb/2026
MannKind USD 947M 794M Feb/2026
Minerva Neurosciences USD 43M 5M Dec/2023
Nektar Therapeutics USD 113M 4M Sep/2023
Pfizer USD 152.89B 11.32B Feb/2026
Rigel Pharmaceuticals USD 188M 36M Sep/2023
United Therapeutics USD 25.18B 4.2B Feb/2026
Vanda Pharmaceuticals USD 243M 136M Dec/2023